Sugi Predict

Sugi Predict / Targets / LCLAT1

LCLAT1

Lysocardiolipin acyltransferase 1 · Q6UWP7 · LCLAT1 on Sugi Atlas →

2,952 patent compounds predicted against LCLAT1, 1,741 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2113651 SCHEMBL2113651 1.00 20/20
SCHEMBL4397094 SCHEMBL4397094 0.61 20/20
SCHEMBL10182438 SCHEMBL10182438 0.56 19/20
SCHEMBL12473754 SCHEMBL12473754 0.51 16/20
SCHEMBL2461145 SCHEMBL2461145 0.59 11/20
SCHEMBL2739997 SCHEMBL2739997 0.67 10/20
SCHEMBL12473474 SCHEMBL12473474 0.52 10/20
SCHEMBL13571048 SCHEMBL13571048 0.51 10/20
SCHEMBL13571090 SCHEMBL13571090 0.59 9/20
SCHEMBL13570782 SCHEMBL13570782 0.52 9/20
SCHEMBL2456473 SCHEMBL2456473 0.51 9/20
SCHEMBL2462175 SCHEMBL2462175 0.51 9/20
SCHEMBL947645 SCHEMBL947645 0.48 9/20
SCHEMBL4770058 SCHEMBL4770058 0.48 9/20
SCHEMBL13571014 SCHEMBL13571014 0.58 8/20
SCHEMBL11609635 SCHEMBL11609635 0.57 8/20
SCHEMBL13570837 SCHEMBL13570837 0.56 8/20
SCHEMBL13570929 SCHEMBL13570929 0.56 8/20
SCHEMBL4320689 SCHEMBL4320689 0.54 8/20
SCHEMBL13570918 SCHEMBL13570918 0.54 8/20

Clinical trials — most relevant to LCLAT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency PHASE2/PHASE3COMPLETED
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) PHASE1COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Epidemiology of Atherosclerosis nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
The Classification and Cause of Leukodystrophies of Unknown Cause nanCOMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy nanCOMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile nanWITHDRAWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Natural History of the Leukodystrophies nanCOMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects) nanUNKNOWN
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
for Adipose Tissue DIabetes VAriants (fATDIVA) nanCOMPLETED
Study of Chediak-Higashi Syndrome nanRECRUITING
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses nanCOMPLETED
LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study nanRECRUITING
Lysosomal Acid Lipase (LAL) Deficiency Registry nanRECRUITING
Evaluation of Cascade Screening for Elevated Lipoprotein(a) nanACTIVE_NOT_RECRUITING
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia nanCOMPLETED
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism nanCOMPLETED
The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation nanRECRUITING
Abnormal Lipids - Causes and Effects nanRECRUITING
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LCLAT1 binder may also engage these)

ProteinNameSimilarity
Q3UN02 — 0.998 Q3UN02 →
Q5F3X0 — 0.995 Q5F3X0 →
Q20800 — 0.994 Q20800 →
Q6IWY1 — 0.988 Q6IWY1 →
Q92604 — 0.987 Q92604 →
Q12185 — 0.986 Q12185 →
Q9SYC8 — 0.986 Q9SYC8 →
Q8LG50 — 0.986 Q8LG50 →
Q6NYV8 — 0.984 Q6NYV8 →
A3KGT9 — 0.983 A3KGT9 →
Q9XFW4 — 0.983 Q9XFW4 →
Q91YX5 — 0.983 Q91YX5 →
Q53EU6 — 0.983 Q53EU6 →
O94361 — 0.983 O94361 →
Q80TN5 — 0.982 Q80TN5 →
Q61586 — 0.982 Q61586 →
Q80TL1 — 0.981 Q80TL1 →
Q5ZLL8 — 0.981 Q5ZLL8 →
Q28C60 — 0.981 Q28C60 →
Q11087 — 0.981 Q11087 →
Q8IUH5 — 0.981 Q8IUH5 →
Q5GJ77 — 0.981 Q5GJ77 →
Q0KHU5 — 0.981 Q0KHU5 →
Q6DCK1 — 0.980 Q6DCK1 →
Q41745 — 0.980 Q41745 →
O18037 — 0.980 O18037 →
Q9P7P0 — 0.980 Q9P7P0 →
Q09225 — 0.980 Q09225 →
O60095 — 0.980 O60095 →
ADCY2 Adenylate cyclase type 2 0.980 landscape →